FOLH1 and neoplasm: Thus, such tumor marker oscillations should not lead to discontinuation of PSMA-RLT, in particular in patients with initial decline followed by a rise in PSA levels, as this scenario may be commonly mistaken as disease progression, especially in the absence of radiological progression.